Almost five years after debuting his first biotech company, noted writer and oncologist Siddhartha Mukherjee has officially unveiled his second: Myeloid Therapeutics. The new company, based in Cambridge, Mass., launched Wednesday with a $50 million Series A.
Myeloid is putting a twist on cell cancer therapies like CAR-T that are already successful in blood cancers and using a similar idea to take on conditions like glioblastoma, which form solid tumors. It will use so-called myeloid cells, the collective term for some kinds of blood and immune cells, to trigger the rest of a person’s immune system.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
